Literature DB >> 8165051

Interactions of steroid, methotrexate, and radiation determine neurotoxicity in an animal model to study therapy for childhood leukemia.

P J Mullenix1, W J Kernan, A Schunior, A Howes, D P Waber, S E Sallan, N J Tarbell.   

Abstract

Children with leukemia receive CNS therapy to improve long-term survival. Neurotoxic effects, such as cognitive impairment, have been associated with this therapy. A rat model was developed to determine which agent, or combination of agents, in CNS therapy causes neurotoxicity. The agents examined were cranial irradiation (1000 cGy), methotrexate (2 or 4 mg/kg, intraperitoneally), and prednisolone (18 or 36 mg/kg, intraperitoneally). Young Sprague-Dawley rats were exposed to each agent alone or to two- or three-agent combinations. Each therapy had matched controls that received sham radiation and/or intraperitoneal saline. Subsequent to exposure, spontaneous behavior was tested using a computer pattern recognition system, which recorded and classified behavior in a novel environment. Behavioral initiations, total times, and time structures were compared in therapy and control groups. Combined rather than single-agent therapies had more behavioral effects, and these were dose- and sex-dependent. Synergistic interactions between agents caused behavioral deficits, and components of the combination determined the abnormality. Some combinations interacted antagonistically, and thus mitigated behavioral deficits. Prednisolone was clearly pivotal to behavioral outcome. A low prednisolone dose antagonized methotrexate preventing deficits, whereas a higher prednisolone dose altered behavior by enhancing effects of methotrexate and radiation. These findings emphasize that steroids are important in agent interactions. Their role in morbidity associated with leukemia treatment protocols may be equally important as that of methotrexate and cranial irradiation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8165051     DOI: 10.1203/00006450-199402000-00009

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  7 in total

1.  Effects of early chemotherapeutic treatment on learning in adolescent mice: implications for cognitive impairment and remediation in childhood cancer survivors.

Authors:  Emily B Bisen-Hersh; Philip N Hineline; Ellen A Walker
Journal:  Clin Cancer Res       Date:  2013-04-17       Impact factor: 12.531

2.  Investigating verbal and visual auditory learning after conformal radiation therapy for childhood ependymoma.

Authors:  Marcos Di Pinto; Heather M Conklin; Chenghong Li; Xiaoping Xiong; Thomas E Merchant
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-09-23       Impact factor: 7.038

3.  Effects of chemotherapeutic agents 5-fluorouracil and methotrexate alone and combined in a mouse model of learning and memory.

Authors:  John J Foley; Robert B Raffa; Ellen A Walker
Journal:  Psychopharmacology (Berl)       Date:  2008-05-08       Impact factor: 4.530

4.  Disruption of learning processes by chemotherapeutic agents in childhood survivors of acute lymphoblastic leukemia and preclinical models.

Authors:  Emily B Bisen-Hersh; Philip N Hineline; Ellen A Walker
Journal:  J Cancer       Date:  2011-05-19       Impact factor: 4.207

5.  The impact of therapy for childhood acute lymphoblastic leukaemia on intelligence quotients; results of the risk-stratified randomized central nervous system treatment trial MRC UKALL XI.

Authors:  Christina Halsey; Georgina Buck; Sue Richards; Faraneh Vargha-Khadem; Frank Hill; Brenda Gibson
Journal:  J Hematol Oncol       Date:  2011-10-13       Impact factor: 17.388

Review 6.  Neurotoxic Effects of Childhood Cancer Therapy and Its Potential Neurocognitive Impact.

Authors:  Nicholas S Phillips; Elizabeth S Duke; Hannah-Lise T Schofield; Nicole J Ullrich
Journal:  J Clin Oncol       Date:  2021-04-22       Impact factor: 50.717

Review 7.  Aging in Adult Survivors of Childhood Cancer: Implications for Future Care.

Authors:  Ilse Schuitema; Tyler Alexander; Melissa M Hudson; Kevin R Krull; Kim Edelstein
Journal:  J Clin Oncol       Date:  2021-04-22       Impact factor: 50.717

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.